Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | CheckMate 9KD: finding novel drug combinations for patients in all stages of treatment

Karim Fizazi • 1 Jun 2018
ASCO 2018
Genitourinary Cancer Prostate Cancer Docetaxel Enzalutamide Nivolumab Rucaparib
CheckMate 9KD

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Karim Fizazi, MD, PhD, of the University of Paris-Sud, Orsay, France, presents the objectives and motivations behind the CheckMate 9KD trial (NCT03338790). This trial investigated nivolumab in combination with either rucaparib, docetaxel or enzalutamide in men with castration-resistant metastatic prostate cancer. Prof. Fizazi highlights how this trial was created to help find novel drug combinations that could be given to different patients.

More from Karim Fizazi

1:30
VISION trial: future research
Karim Fizazi • 7 Jun 2021
4:48
VISION: Lu-177-PSMA-617 in mCRPC
Karim Fizazi • 7 Jun 2021
1:34
Lu-PSMA-617 deployment and future of prostate cancer treatment
Karim Fizazi • 7 Jun 2021
2:05
Abiraterone in metastatic castration-sensitive prostate cancer
Karim Fizazi • 1 Jun 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals